First Tracks Biotherapeutics (TRAX) — Net Asset Quality Index
First Tracks Biotherapeutics (TRAX) has a Net Asset Quality Index of 92.2% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $183.14 Million minus total liabilities of $14.34 Million yields net assets of $168.80 Million. A higher index indicates a stronger, lower-leverage balance sheet. Explore First Tracks Biotherapeutics (TRAX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
First Tracks Biotherapeutics Net Asset Quality Index Over Time (2023–2025)
This chart shows how First Tracks Biotherapeutics's Net Asset Quality Index has evolved across 3 annual periods from 2023 to 2025. As of June 2026, the index stands at 92.2%, representing net assets of $168.80 Million against total assets of $183.14 Million USD. See TRAX net asset value for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for First Tracks Biotherapeutics (2023–2025)
The table below presents the year-by-year Net Asset Quality Index for First Tracks Biotherapeutics from 2023 to 2025, covering 3 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see First Tracks Biotherapeutics (TRAX) total market value.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 87.0% | $287.49 Million | $330.55 Million | $43.05 Million | ▼ -1.6 pp |
| 2024 | 88.6% | $391.60 Million | $441.89 Million | $50.30 Million | ▼ -3.7 pp |
| 2023 | 92.3% | $409.85 Million | $444.11 Million | $34.26 Million | — |